安福隆治疗慢性乙型肝炎临床研究

Therapeutical Effect of Anfuron (Interferon a-2b) on Patients with Chronic Hepatitis B

目的:观察安福隆基因工程干扰素α-2b治疗慢性乙型肝炎的疗效.方法:94例患者予安福隆3×106U,肌肉注射,隔日1次,持续3个月,有效者继续治疗3个月.无效者及另外22例患者予安福隆5×106U,肌肉注射,隔日1次,疗程为6个月.所有患者均于治疗前、治疗中及治疗结束时检测HBV标志物,肝功能,并定性、定量检测HBVDNA.结果:3×106U治疗组中完全及部分反应病例83人,占65.1%,无反应者11例,将其转入5×106U组中,5×106U治疗组中完全及部分反应病例占69.7%,完全反应病例HBV DNA拷贝数低于不反应者.病程短者完全反应比例高.结论:安福隆治疗慢性乙型肝炎疗效较为理想,疗效与患者病毒血症水平和病程密切相关.

Objectives To evaluate the clinical effect of Anferon (Interferon a-2b) in the treatment of patients with chronic hepatitis B. Methods: Groupl: 94 patients were given Anferon 3X 106U every two days for three months, of whom ones showed better effect were given Anferon for another 3 months. 11 showing no effect and 22 cases were given Anferon 5X106U every two days for six months. HBV markers, ALT and the concentration of HBV DNA in serum were detected before, during and at the end of the treatment. Results: In 3X106U group, the patients with complete and part reaction occupied 65.1%, and in 5 X106U group, these patients occupied 69.7%. The copies of HBV DNA were lower in patients with complete reaction than that in part reacting patients. The completely reacting patients had short clinical courses. Conclusion: Anferon showed better effect in the treatment of chronic hepatitis B. And it's therapeutical effect is closely correlated with the clinical course and the level of hepatitis B virus in serum.